British Biotech makes a mark at the London Stock Exchange

Like Comment

With constant attempts to develop new antibiotics, Destiny Pharma has been working hard to keep itself in the race for development in the world of science. The recent update notes that the British biotech firm has started trading its shares on the London Stock Exchange with the intention to support its search for antibiotics to fight resistant bacteria like MRSA. Based in Brighton, UK, Destiny Pharma entered the AIM market with an initial placement of £15.3M and had a starting market cap placed at £65.4M as it opened last month. The achievement isn’t as easy as finding smart roofing solutions and the biotech firm has been rigorous with its efforts.

The biotech firm made a note that the funds raised in the process would be used to advance the developmental struggle of the company’s lead drug candidate XF-73. This compound is now being tested as an alternative to many traditional antibiotics to prevent Staphylococcus aureus infections that include the antibiotic-resistant MRSA strain caused after surgery. XF-73 is a dicationic porphyrin molecule that belongs to a completely different class of antibiotics called XF drugs. It is being learned that these drugs can kill bacteria in many growth states that usually inhibit growth in active cultures. They also seem to be good enough to attack the bacteria at the time when they form biofilms.

Talking about the precise action of XF-73, it is still unknown beyond the fact that it can target the bacterial membrane of Gram-positive bacteria and even a few Gram-negative species. The precise mechanism might be effective, but there is a lot more to be discovered in this case. Interestingly, Destiny Pharma has previously published results relating to XF-73 noting that it has a distinct mechanism of action as compared to the other membrane-targeting antibiotics like mupirocin, daptomycin, ancomycin, retapamulin, and fusidic acid.

The biotic firm is trying to prevent some post-surgery infections with this promising candidate. Till date, the company has not found any bacterial strains resistant to the newly found antibiotic. However, it might have its disadvantages because of mupirocin, which is an antibiotic currently used to prevent infections. Mupirocin has previously been linked to the possible development of MSRA strains, putting patients at greater risk.

Destiny Pharma has constantly been looking at ways in which they can do a lot good for humanity. If successful, they might enter the big market to push new products desperately to increase the antibiotic-resistant bacteria that renders doctors useless against infections. 


Marshal, LMG Solutions

Stephen Marshall is a Director of Be Basic CEO with extensive experience in marketing and financial services in Meridian, Idaho.